Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Xerostomia 1Oligodendroglioma 1Neuroblastoma 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1Adenoviridae Infections 1

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Lomustine 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Genetic Engineering × Clear all
NCT01156584 2018-05-21

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Tocagen Inc.

Phase 1 Completed
54 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡